3 reports

  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Pipeline by VG Life Sciences, Inc., H1 2016
  • Products under Development by Companies, H1 2016

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides...

  • Cancer
  • Pharmaceutical
  • United States
  • Product Initiative
  • VG Life Sciences, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.